NEW YORK (GenomeWeb News) — Accelr8 last week reported that third-quarter revenues were stable while R&D spending fell by half and losses narrowed 40 percent.
 
Total receipts for the three months ended April 30 increased to $22,700 from $19,800 year over year.
 
The company’s only revenue came from its OptiChem product line.
  
R&D spending was slashed to $247,500 from $490,000 year over year.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.